SEC Form 4 · accession 0001209191-17-060965
SteadyMed Ltd. · STDY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David W. Nassif
Officer — EVP and CFO
Period of report
Nov 13, 2017
Accepted (ET)
Nov 15, 2017 · 5:38 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001619087
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F2 | Nov 13, 2017 | A | 44,315 | $0.00 | A | 44,315 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of SteadyMed Ltd. ordinary shares.
- F2RSU shall vest in two tranches. On June 30, 2018, 22,158 shall vest. Thereafter, on the date that the New Drug Application for Trevyent is approved by the U.S. Food and Drug Administration, the remaining balance of 22,157 shares shall vest.